Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Fineline Cube Dec 30, 2025
Company Deals

Edge Medical Raises HK$1.2 Billion in Hong Kong IPO to Fund Surgical Robot Pipeline

Fineline Cube Dec 30, 2025
Company Deals

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug

Fineline Cube Dec 30, 2025
Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

CSPC Pharmaceutical Receives IND Approvals for GLP-1/GIP Agonist and Triple-Combo Diabetes Drug

Fineline Cube Dec 30, 2025
Company Drug

Hengrui’s HRS-6257 Receives IND Approval for Novel Pain Therapy in China

Fineline Cube Dec 30, 2025
Company Digital Drug

China Medical System Partners with MabGeek for Innovative Drug MG-K10

Fineline Cube Jan 26, 2025

China Medical System Holdings (CMS; HKG: 0867) has announced a new license agreement with MabGeek...

Company Drug

BioCity Biopharma Launches Phase III Study for Kidney Disease Drug SC0062

Fineline Cube Jan 25, 2025

BioCity Biopharma, a leading biopharmaceutical company, has announced the initiation of a Phase III clinical...

Company Deals

ConjuStar Raises RMB100 Million to Advance X-Drug Conjugates Pipeline

Fineline Cube Jan 24, 2025

ConjuStar, a specialist in X-Drug conjugates (XDCs) based in Tianjin, has reportedly raised RMB100 million...

Company Drug

Hengrui’s Long-Acting Insulin Analogue Accepted for Review by China’s NMPA

Fineline Cube Jan 24, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that its market filing for...

Company Deals

AbbVie Partners with Neomorph on Molecular Glue Degraders for Oncology and Immunology

Fineline Cube Jan 24, 2025

US-based pharmaceutical giant AbbVie (NYSE: ABBV) has entered into a collaboration and option-to-license agreement with...

Company Medical Device

Sino Medical Sciences Wins Peru Approval for Coronary Balloon Catheter

Fineline Cube Jan 24, 2025

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced receiving marketing approval from Peru’s...

Company Drug

Shenzhen Beike Initiates First Chinese Stem Cell Study for Systemic Lupus Erythematosus

Fineline Cube Jan 24, 2025

China-based stem cell specialist Shenzhen Beike Biotechnology Co., Ltd has announced the initiation of a...

Company Medical Device

Accuray’s Tomo C System Completes Treatment of First 100 Patients in China

Fineline Cube Jan 24, 2025

US-based medical device firm Accuray Inc. (NASDAQ: ARAY) has announced the completion of treating the...

Company Deals

Ascentage Pharma Prices US IPO at USD 17.25 per ADS

Fineline Cube Jan 24, 2025

China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) has announced the pricing of its initial public...

Company Drug

United Laboratories’ Biosimilar Semaglutide Accepted for Review by China’s NMPA

Fineline Cube Jan 24, 2025

Hong Kong-listed United Laboratories International Holdings Ltd (HKG: 3933) has announced that its market filing...

Company Drug

Beijing Aosaikang’s ASKB589 Shows Promise in Phase I/II Study for Gastric Cancer

Fineline Cube Jan 24, 2025

China’s Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has unveiled the latest results from a...

Company Drug

Biogen’s Higher-Dose Spinraza Regimen Under Review by FDA and EMA

Fineline Cube Jan 24, 2025

US-based biopharmaceutical company Biogen (NASDAQ: BIIB) has submitted supplemental New Drug Applications (sNDAs) to the...

Company Deals

Novo Nordisk Partners with IMMvention on BACH1 Program for Sickle Cell Disease

Fineline Cube Jan 24, 2025

Denmark-based Novo Nordisk A/S (NYSE: NVO) has entered into a strategic collaboration and license agreement...

Company

Zai Lab’s ZL-1310 Granted Orphan Drug Designation by FDA for SCLC

Fineline Cube Jan 23, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced that the US Food...

Company Deals

Simnova, Orna Expand Partnership to Develop BCMA-Targeted RNA Therapies

Fineline Cube Jan 23, 2025

Shanghai Simnova Biotech Co., Ltd. (Simnova), an affiliate of Simcere Investment Group, has expanded its...

Company

Johnson & Johnson Reports Q4 Growth, Projects 2025 Sales Outlook

Fineline Cube Jan 23, 2025

US-based Johnson & Johnson (J&J, NYSE: JNJ) has released its Q4 2024 financial results, reporting...

Company Drug

YolTech Initiates Study for YOLT-204 in Transfusion-Dependent Beta-Thalassemia

Fineline Cube Jan 23, 2025

Shanghai-based YolTech Therapeutics, a biotech startup specializing in lipid nanoparticle delivery and gene editing, has...

Company Drug

Haichang Bio’s siRNA Drug HC016 Cleared for US Clinical Trials

Fineline Cube Jan 23, 2025

China-based Zhejiang Haichang Biotech Co., Ltd has announced that its siRNA drug, HC016 complex lipid,...

Company Deals

iMBIORAY Raises RMB 100 Million in Series A+ for NK Cell Therapies

Fineline Cube Jan 23, 2025

Hangzhou-based cell therapy specialist iMBIORAY has reportedly raised close to RMB 100 million (USD 13.7...

Company Drug Medical Device

Abbott Labs Posts Q4 Growth, Projects Strong 2025 Outlook

Fineline Cube Jan 23, 2025

US-based Abbott Laboratories (NYSE: ABT) has released its Q4 2024 financial results, reporting an 8.8%...

Posts pagination

1 … 158 159 160 … 603

Recent updates

  • Broncus Medical Acquires Valgen Stake from Venus for $15 Million
  • CSPC Pharmaceutical Receives IND Approvals for GLP-1/GIP Agonist and Triple-Combo Diabetes Drug
  • Hengrui’s HRS-6257 Receives IND Approval for Novel Pain Therapy in China
  • Recbio’s REC610 Shingles Vaccine NDA Accepted by NMPA, Challenging GSK’s Shingrix
  • Edge Medical Raises HK$1.2 Billion in Hong Kong IPO to Fund Surgical Robot Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Company Drug

CSPC Pharmaceutical Receives IND Approvals for GLP-1/GIP Agonist and Triple-Combo Diabetes Drug

Company Drug

Hengrui’s HRS-6257 Receives IND Approval for Novel Pain Therapy in China

Company Drug

Recbio’s REC610 Shingles Vaccine NDA Accepted by NMPA, Challenging GSK’s Shingrix

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.